CD69 and non-small cell lung carcinoma: On CD45+CD3−CD20− NK cells, PHA could increase the percentage of CD69+ cells from 6.1% to 76.1% in the NSCLC patients’ group, and trend to raise the percentage of CD69+ cells in the healthy volunteers’ group (Fig. 3D).